Pharmacogenetics of obstetric therapeutics

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension. Preterm Labor Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).

Original languageEnglish (US)
Title of host publicationPrinciples of Pharmacogenetics and Pharmacogenomics
PublisherCambridge University Press
Pages202-216
Number of pages15
Volume9780521885379
ISBN (Electronic)9781139051194
ISBN (Print)9780521885379
DOIs
StatePublished - Jan 1 2012

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Pharmacogenetics of obstetric therapeutics'. Together they form a unique fingerprint.

  • Cite this

    Haas, D., & Renbarger, J. (2012). Pharmacogenetics of obstetric therapeutics. In Principles of Pharmacogenetics and Pharmacogenomics (Vol. 9780521885379, pp. 202-216). Cambridge University Press. https://doi.org/10.1017/CBO9781139051194.021